ATE242319T1 - Deletionsmutanten als impfstoffe gegen cholera - Google Patents

Deletionsmutanten als impfstoffe gegen cholera

Info

Publication number
ATE242319T1
ATE242319T1 AT93916907T AT93916907T ATE242319T1 AT E242319 T1 ATE242319 T1 AT E242319T1 AT 93916907 T AT93916907 T AT 93916907T AT 93916907 T AT93916907 T AT 93916907T AT E242319 T1 ATE242319 T1 AT E242319T1
Authority
AT
Austria
Prior art keywords
cholera
vaccine
deletion mutants
vaccines against
against cholera
Prior art date
Application number
AT93916907T
Other languages
English (en)
Inventor
John J Mekalanos
David Beattie
Kevin Killeen
Yichen Lu
Original Assignee
Harvard College
Virus Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Virus Res Inst filed Critical Harvard College
Application granted granted Critical
Publication of ATE242319T1 publication Critical patent/ATE242319T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/63Vibrio
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/909Vibrio

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93916907T 1992-07-06 1993-07-01 Deletionsmutanten als impfstoffe gegen cholera ATE242319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90938292A 1992-07-06 1992-07-06
PCT/US1993/006270 WO1994001533A1 (en) 1992-07-06 1993-07-01 Deletion mutants as vaccines for cholera

Publications (1)

Publication Number Publication Date
ATE242319T1 true ATE242319T1 (de) 2003-06-15

Family

ID=25427152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916907T ATE242319T1 (de) 1992-07-06 1993-07-01 Deletionsmutanten als impfstoffe gegen cholera

Country Status (16)

Country Link
US (1) US5631010A (de)
EP (1) EP0672116B1 (de)
JP (2) JP4179627B2 (de)
CN (1) CN1083524A (de)
AT (1) ATE242319T1 (de)
AU (1) AU4660893A (de)
BR (1) BR9306707A (de)
CA (1) CA2139655C (de)
DE (1) DE69333028T2 (de)
DK (1) DK0672116T3 (de)
ES (1) ES2199944T3 (de)
MX (1) MX9303992A (de)
PT (1) PT672116E (de)
TW (1) TW266228B (de)
WO (1) WO1994001533A1 (de)
ZA (1) ZA934736B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882653A (en) * 1983-03-04 1999-03-16 The University Of Maryland System Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
CA2156191A1 (en) * 1993-02-22 1994-09-01 Stephen B. Calderwood Heterologous antigens in live cell vaccine strains
US6203799B1 (en) 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
KR100348156B1 (ko) * 1993-10-08 2003-01-06 유니버시티 오브 매릴랜드 앳 발티모어 비브리오콜레래이01(cvd111)및비-01(cvd112와cvd112rm)혈청형백신균주,그것의제조방법및그것의생산물
CN1058522C (zh) * 1994-04-01 2000-11-15 中国预防医学科学院流行病学微生物研究所 一种霍乱弧菌新菌株及其活菌苗
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1998023763A1 (en) * 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
JP4086945B2 (ja) * 1996-12-10 2008-05-14 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 非毒性V.Cholerae株の単離法およびその株由来のコレラワクチンの製造法
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP0887403A3 (de) * 1997-06-27 2000-12-06 Chiron S.P.A. Abgeschwächte Stämme von Vibrio cholerae
EP0928831B1 (de) * 1997-12-10 2006-05-03 Council of Scientific and Industrial Research Choleraorganismen, Impfstoffe und ihre Verwendung
FR2772791B1 (fr) * 1997-12-24 2000-01-28 Staubli Sa Ets Actionneur rotatif electrique pour la formation de la foule sur un metier a tisser, mecanique d'armure et metier a tisser
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
WO2000011181A1 (en) 1998-08-20 2000-03-02 Connaught Laboratories Limited NUCLEIC ACID MOLECULES ENCODING INCLUSION MEMBRANE PROTEIN C OF $i(CHLAMYDIA)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
IL148247A0 (en) * 1999-08-24 2002-09-12 Teva Pharma A vaccine composition and method of using the same
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
CN1484700A (zh) 2000-11-02 2004-03-24 �¼��¹�����ѧ aopB基因,蛋白,同系物,片段和它们的变体,以及它们在细胞表面展示方面的应用
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
US20060099229A1 (en) * 2004-11-05 2006-05-11 Universiti Sains Malaysia Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
US8287855B2 (en) * 2007-04-24 2012-10-16 Celldex Therapeutics, Inc. V. cholerae hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity
CN101519440B (zh) * 2008-02-29 2012-02-08 中国科学院海洋研究所 一种交叉保护性疫苗抗原及其制备方法和应用
KR101722802B1 (ko) * 2009-09-16 2017-04-03 엠에스디 웰컴 트러스트 힐레맨 랩스 피브이티. 리미티드 콜레라 및 장독소생성 이. 콜라이(etec) 설사에 대한 백신
CN103468623B (zh) * 2011-09-30 2016-01-06 中山百慧基因科技有限公司 基因工程用工具菌及其应用
WO2018111018A2 (ko) * 2016-12-16 2018-06-21 한양대학교 에리카산학협력단 플라스미드 기반의 ctx 파지 복제시스템 및 ctx 파지에 감염되고 콜레라 독소를 생산할 수 있는 비브리오 콜레라 균주
US11136358B2 (en) 2016-12-16 2021-10-05 Industry-University Cooperation Foundation Hanyang University Erica Campus Plasmid-based CTX phage replication system and vibrio cholerae strain that can be infected by CTX phage and can be used for cholera toxin production
EP3651796A4 (de) * 2017-07-12 2021-06-30 The Brigham and Women's Hospital, Inc. Abgeschwächter cholera-lebendimpfstoff mit probiotischen eigenschaften

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
US4882278A (en) * 1983-04-29 1989-11-21 President And Fellows Of Harvard College Non-toxinogenic vibrio cholerae mutants
US5098998A (en) * 1987-04-29 1992-03-24 President And Fellows Of Harvard College Cholera vaccines and peptides
AU656730B2 (en) * 1990-06-05 1995-02-16 University Of Maryland At Baltimore Method of isolating restriction fragment deletions in vibrio cholerae, and products thereof

Also Published As

Publication number Publication date
US5631010A (en) 1997-05-20
EP0672116B1 (de) 2003-06-04
DE69333028T2 (de) 2004-04-22
DK0672116T3 (da) 2003-10-06
CN1083524A (zh) 1994-03-09
DE69333028D1 (de) 2003-07-10
WO1994001533A1 (en) 1994-01-20
JP4179627B2 (ja) 2008-11-12
JP2004159660A (ja) 2004-06-10
AU4660893A (en) 1994-01-31
EP0672116A4 (de) 1996-06-12
CA2139655A1 (en) 1994-01-20
MX9303992A (es) 1995-01-31
EP0672116A1 (de) 1995-09-20
JPH07508885A (ja) 1995-10-05
BR9306707A (pt) 1998-12-08
PT672116E (pt) 2003-10-31
TW266228B (de) 1995-12-21
ES2199944T3 (es) 2004-03-01
CA2139655C (en) 2008-05-13
ZA934736B (en) 1994-01-24

Similar Documents

Publication Publication Date Title
ATE242319T1 (de) Deletionsmutanten als impfstoffe gegen cholera
EP1170016A3 (de) Impfstoff auf Urease-Basis gegen Helicobacter Infektionen
DK0877624T3 (da) Vaccine med udgangspunkt i streptokokkisk C5A-peptidase
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
MY129006A (en) Vaccine composition
CA2082155A1 (en) Swine pneumonia vaccine and method of preparation
ES2121820T3 (es) Vacuna de conjugados de polisacaridos de neumococos.
AU1955088A (en) Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic AMP
ES8505719A1 (es) Procedimiento de preparar mutantes de delecion vivos y metodo de preparar vacunas
SE9003198D0 (sv) Fish vaccine comprising a virulent, invasive bacterium
NZ240538A (en) Avirulent salmonella typhi strains and immunogenic compositions.
NZ335050A (en) Helicobacter pylori live vaccine
TR200002974T2 (tr) Bruselloza karşı canlı aşı
PL299739A1 (en) Non-virulent rabies vaccine, double non-virulent mutant of rabies virus and method of obtaining such mutant
GR3018529T3 (en) Nematode vaccine.
HUP9702355A2 (hu) Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
PT603386E (pt) Imunizacao parenterica contra rotavirus
NO996428L (no) Anti-Vibrio anguillarum-vaksine (GAVA-3) for forhindring av vibriosen i piggvar og laksefisk og fremgangsmåten for fremstilling av slike vaksiner
IT8722791A0 (it) Attenuato cosi' ottenuto. procedimento per la preparazione di un ceppo mutante migliorato di bordetella bronchiseptica utile per un vaccino attenuato vivo per la protezione da infezioni di b.bronchiseptica e vaccino ar vivo
TH36573B (th) สายพันธุ์กลายชนิดของสารกรรมพันธุ์ที่ขาดแหว่งไปนำมาใช้เป็นวัคซีนอหิวาต์

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0672116

Country of ref document: EP

REN Ceased due to non-payment of the annual fee